Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vor Biopharma Inc. VOR
$4.20
-$0.09 (-2.10%)
На 18:04, 12 мая 2023
+42.86%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
266400902.00000000
-
week52high
7.57
-
week52low
3.48
-
Revenue
0
-
P/E TTM
-1
-
Beta
-0.66921200
-
EPS
-2.27000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 15 авг 2022 г. |
| Wedbush | Outperform | 26 июл 2022 г. | |
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 13 мая 2022 г. |
| Goldman Sachs | Neutral | 27 апр 2022 г. | |
| Oppenheimer | Outperform | Outperform | 14 ноя 2022 г. |
| Barclays | Overweight | Overweight | 11 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | A | 20923554 | 11627907 | 09 дек 2022 г. |
| Attar Eyal C. | A | 364000 | 364000 | 11 окт 2022 г. |
| ANG ROBERT | A | 172500 | 172500 | 13 сент 2022 г. |
| ANG ROBERT | A | 584572 | 172500 | 13 сент 2022 г. |
| Jorgensen Nathan D. | A | 86000 | 86000 | 01 сент 2022 г. |
| Jorgensen Nathan D. | A | 115269 | 86000 | 01 сент 2022 г. |
| Chakraborty Tirtha | A | 76000 | 76000 | 01 сент 2022 г. |
| Chakraborty Tirtha | A | 96980 | 76000 | 01 сент 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 16911 | 16911 | 14 июн 2022 г. |
| Resnick Joshua | A | 16911 | 16911 | 14 июн 2022 г. |
Новостная лента
Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference
GlobeNewsWire
12 янв 2023 г. в 08:00
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities' 3rd Annual Oncology Conference.
Vor Bio to Participate in Upcoming Investor Conferences
GlobeNewsWire
22 ноя 2022 г. в 08:00
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Vor Bio to Participate in Upcoming Investor Conferences
GlobeNewsWire
01 ноя 2022 г. в 08:00
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Vor Bio to Participate in Upcoming Investor Conferences
GlobeNewsWire
06 сент 2022 г. в 16:15
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?
Zacks Investment Research
01 сент 2022 г. в 11:34
The consensus price target hints at a 298.3% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.